Moderna公司(股票代码MRNA)今日盘中大涨6.43%,引起市场广泛关注。这与该公司从美国政府获得5.9亿美元资金支持密切相关,该资金将用于加快其禽流感疫苗mRNA-1018的开发进度。
据悉,Moderna将根据一项早中期研究的初步数据,把这款实验性注射剂推进到后期临床试验阶段,并计划在即将召开的医学会议上展示相关数据。此前,该公司因呼吸道合胞病毒(RSV)疫苗上市缓慢、新冠疫苗需求下降等因素,下调了2025年销售预期,股价曾一度遭受重创。
来自政府的资金支持无疑为Moderna新药研发注入新动力,市场也因而重燃对该公司在医疗健康领域长期发展前景的信心。尽管Moderna今年以来股价已大跌三分之二,但在禽流感疫苗研发获重大利好消息的推动下,公司重振雄风的希望再次点燃。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.